Senores Pharmaceuticals Limited is set to launch its initial public offering (IPO) from December 20 to December 24, 2024, aiming to raise approximately ₹582 crores. The offering includes a fresh issue of ₹500 crores and an offer for sale of up to 2.1 million equity shares by existing shareholders. Established in 2017, Senores focuses on developing and manufacturing a range of pharmaceutical products primarily for regulated markets like the US, Canada, and the UK, while also catering to emerging markets.
₹280
₹391
₹600
Expert Opinions
Market sentiment for the Senores Pharmaceuticals IPO is largely positive, fueled by strong growth metrics and increasing interest in the pharmaceutical sector. Company strengths include a remarkable revenue increase of 507% to ₹214.52 crores in FY24, driven by expanding product sales and a diverse portfolio focused on specialty pharmaceuticals. However, risks and challenges involve potential regulatory hurdles and competition in the pharmaceutical market, which could impact future growth.
The valuation analysis places the price band between ₹372 and ₹391 per share for a total IPO size of approximately ₹582 crores, reflecting a strategic approach to capital raising. From a long-term investment perspective, Senores Pharmaceuticals is well-positioned to leverage its growth trajectory and capitalize on emerging market opportunities.
Investor Considerations
Investors considering the Senores Pharmaceuticals IPO should assess several key aspects. Company performance and fundamentals are strong, with significant revenue growth driven by a diverse portfolio of over 55 products targeted at regulated markets, including the US, Canada, and the UK. The sector outlook is favorable, as the global pharmaceutical market continues to expand, particularly in specialty drugs and injectables. The IPO valuation, set between ₹372 and ₹391 per share for a total issue size of approximately ₹582 crores, reflects a reasonable entry point given the company’s growth trajectory.
Growth prospects are promising, supported by robust R&D capabilities and plans to enhance manufacturing facilities. However, risk factors include high dependence on regulatory approvals and potential market volatility that could impact revenue stability. A long-term investment horizon is advisable, as Senores Pharmaceuticals is well-positioned to capitalize on emerging opportunities in the pharmaceutical sector while navigating inherent industry challenges.
| Date | GMP | Trend |
|---|---|---|
| 29 Dec 2024 12.04 | ₹280 | --- |
| 28 Dec 2024 11.36 | ₹280 | Up |
| 27 Dec 2024 11.12 | ₹230 | --- |
| 26 Dec 2024 11.16 | ₹230 | --- |
| 25 Dec 2024 11.21 | ₹230 | --- |
| 24 Dec 2024 11.01 | ₹230 | Up |
| 23 Dec 2024 11.58 | ₹210 | Up |
| 22 Dec 2024 12.05 | ₹190 | --- |
| 21 Dec 2024 12.38 | ₹190 | Up |
| 20 Dec 2024 10.45 | ₹150 | --- |
| 19 Dec 2024 12.43 | ₹150 | Up |
| 18 Dec 2024 11.54 | ₹00 | --- |
| 17 Dec 2024 12.12 | ₹00 | --- |
FAQs
The Grey Market Premium showed moderate accuracy in predicting Senores Pharmaceuticals’ listing performance. While the GMP of ₹280 predicted a premium of 71.61% over the issue price, the stock delivered a lower gain of 53.45%. With a prediction error of 10.58%, the GMP correctly predicted the positive listing direction but overestimated the magnitude of gains, demonstrating partial reliability as a directional indicator in this case.
Senores Pharmaceuticals IPO Current GMP is ₹280.
Senores Pharmaceuticals IPO Expected Returns is 71.61%.
Senores Pharmaceuticals IPO estimated listing price is ₹671.